Search

A recent study conducted by researchers from Washington University in St. Louis, Missouri, explores the management of adverse events following gene therapy for patients with Duchenne muscular dystrophy (DMD). DMD is a rare neuromuscular disease caused by mutations in the dystrophin gene. The study aims to provide consensus considerations for the evaluation and management of potential treatment-related adverse events (TRAEs) such as vomiting, acute liver injury, myocarditis, and immune-mediated myositis. The interdisciplinary panel of specialists developed these considerations through a modified Delphi process. The research was supported by Sarepta Therapeutics and has been peer-reviewed. [Extracted from the article]

Madison, Wisconsin, United States, North and Central America, Health and Medicine, Pediatrics Keywords for this news article include: Madison, Wisconsin, Pediatrics, United States, Health and Medicine, North and Central America. Keywords: Madison; Wisconsin; United States; North and Central America; Health and Medicine; Pediatrics EN Madison Wisconsin United States North and Central America Health and Medicine Pediatrics 599 599 1 10/24/23 20231027 NES 231027 2023 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Health and Medicine - Pediatrics is the subject of a report. [Extracted from the article]

Little Rock, Arkansas, United States, North and Central America, Child Neurology, Dyskinesias, Dystonia, Health and Medicine, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neurologic Manifestations Keywords: Little Rock; Arkansas; United States; North and Central America; Child Neurology; Dyskinesias; Dystonia; Health and Medicine; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neurologic Manifestations EN Little Rock Arkansas United States North and Central America Child Neurology Dyskinesias Dystonia Health and Medicine Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neurologic Manifestations 413 413 1 04/24/23 20230424 NES 230424 2023 APR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Nervous System Diseases and Conditions - Dystonia is the subject of a report. [Extracted from the article]

Atrophic Muscular Disorders, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Cytoskeletal Proteins, Duchenne Muscular Dystrophy, Dystrophin, Epilepsy, Health and Medicine, Membrane Proteins, Muscle Proteins, Muscular Diseases and Conditions, Muscular Dystrophies, Muscular Dystrophy, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neuromuscular Diseases and Conditions Keywords: Atrophic Muscular Disorders; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Cytoskeletal Proteins; Duchenne Muscular Dystrophy; Dystrophin; Epilepsy; Health and Medicine; Membrane Proteins; Muscle Proteins; Muscular Diseases and Conditions; Muscular Dystrophies; Muscular Dystrophy; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neuromuscular Diseases and Conditions EN Atrophic Muscular Disorders Brain Diseases and Conditions Central Nervous System Diseases and Conditions Cytoskeletal Proteins Duchenne Muscular Dystrophy Dystrophin Epilepsy Health and Medicine Membrane Proteins Muscle Proteins Muscular Diseases and Conditions Muscular Dystrophies Muscular Dystrophy Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neuromuscular Diseases and Conditions 428 428 1 03/23/23 20230317 NES 230317 2023 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on duchenne muscular dystrophy. [Extracted from the article]

Antibodies, Pharmaceuticals, Business, Genetics, Neurology, Immunology, Gene Therapy, Bioengineering, Blood Proteins, Regenxbio Inc, Immunoglobulins, Clinical Research, Drugs and Therapies, Health and Medicine, Post-Trial Research, Muscular Dystrophies, Clinical Trials and Studies, Duchenne Muscular Dystrophy, Healthcare Biotechnology Companies, Muscular Diseases and Conditions, Muscular Dystrophy, Musculoskeletal Diseases and Conditions, Nervous System Diseases and Conditions, Neuromuscular Diseases and Conditions, Proteins, Therapy, Atrophic Muscular Disorders Keywords: Antibodies; Pharmaceuticals; Business; Genetics; Neurology; Immunology; Gene Therapy; Bioengineering; Blood Proteins; Regenxbio Inc; Immunoglobulins; Clinical Research; Drugs and Therapies; Health and Medicine; Post-Trial Research; Muscular Dystrophies; Atrophic Muscular Disorders; Clinical Trials and Studies; Duchenne Muscular Dystrophy; Healthcare Biotechnology Companies; Muscular Diseases and Conditions; Muscular Dystrophy; Musculoskeletal Diseases and Conditions; Nervous System Diseases and Conditions; Neuromuscular Diseases and Conditions; Proteins; Therapy EN Antibodies Pharmaceuticals Business Genetics Neurology Immunology Gene Therapy Bioengineering Blood Proteins Regenxbio Inc Immunoglobulins Clinical Research Drugs and Therapies Health and Medicine Post-Trial Research Muscular Dystrophies Atrophic Muscular Disorders Clinical Trials and Studies Duchenne Muscular Dystrophy Healthcare Biotechnology Companies Muscular Diseases and Conditions Muscular Dystrophy Musculoskeletal Diseases and Conditions Nervous System Diseases and Conditions Neuromuscular Diseases and Conditions Proteins Therapy REGENXBIO Inc. (Nasdaq: RGNX) announced that the Phase I/II AFFINITY DUCHENNE(TM) trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients. [Extracted from the article]